RxDoctor Payments Data

Camille Picini

Physician Assistant · Massapequa, NYNPI 1932750114

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $21,669 of the $30,816 with a category attached, or 70.3%. 24 manufacturers reported payments, led by UCB, Inc. at 36.7% of the total. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,816in general payments, 2019–2025

Across 997 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$11K
  • Amgen$5K
  • AbbVie$3K
  • Johnson & Johnson$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • AstraZeneca$932
  • plus $6K from 18 others

What the payments were for

  • Consulting fees$3,84012%
  • Speaking & faculty fees$4,00013%
  • Travel & lodging$9943%
  • Food & beverage$21,66970%
  • Education$3141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,816 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept83$655,770
Humira(Cf) PenAdalimumab24$278,247
Cosentyx Sensoready (2 Pens)Secukinumab11$159,980
Xeljanz XrTofacitinib Citrate24$138,769
OtezlaApremilast16$116,977
ProliaDenosumab59$103,906
BenlystaBelimumab28$53,446
Evenity (2 Syringes)Romosozumab-Aqqg20$48,610
TymlosAbaloparatide14$36,453
Teriparatide12$31,880
RasuvoMethotrexate/Pf29$23,391
Hydroxychloroquine Sulfate422$16,014
MethotrexateMethotrexate Sodium303$7,300
Leflunomide82$5,509
Prednisone280$1,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Prolia, Evenity (2 Syringes)$4,503$269,49395 claims
GSKBenlysta$745$53,44628 claims
Radius Health, Inc.Tymlos$890$36,45314 claims
Alvogen IncTeriparatide$24$31,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →